|
42
|
116
|
4nyvA |
Crystal structure of the bromodomain of human crebbp in complex with a quinazolin-one ligand |
|
42
|
116
|
4nr6A |
Crystal structure of the bromodomain of human crebbp in complex with an oxazepin ligand |
|
2
|
9
|
4mg7C |
Crystal structure of hera-lbd (y537s) in complex with ferutinine |
|
1
|
9
|
4mgdF |
Crystal structure of hera-lbd (y537s) in complex with hpte |
|
2
|
9
|
4mg5C |
Crystal structure of hera-lbd (y537s) in complex with chlordecone |
|
29
|
123
|
4llbA |
Crystal structure of moz double phd finger histone h3k14ac complex |
|
1
|
9
|
4mg9F |
Crystal structure of hera-lbd (y537s) in complex with butylparaben |
|
2
|
9
|
4mgaC |
Crystal structure of hera-lbd (y537s) in complex with 4-tert-octylphenol |
|
1
|
9
|
4mgcF |
Crystal structure of hera-lbd (y537s) in complex with benzophenone-2 |
|
2
|
10
|
4mg8C |
Crystal structure of hera-lbd (y537s) in complex with alpha-zearalanol |
|
28
|
126
|
4lkaA |
Crystal structure of moz double phd finger histone h3k9ac complex |
|
2
|
9
|
4mg6C |
Crystal structure of hera-lbd (y537s) in complex with benzylbutylphtalate |
|
1
|
9
|
4mgbC |
Crystal structure of hera-lbd (y537s) in complex with tcbpa |
|
28
|
126
|
4lk9A |
Crystal structure of moz double phd finger histone h3 tail complex |
|
24
|
124
|
4ljnA |
Crystal structure of moz double phd finger |
|
78
|
260
|
4j5wC |
Crystal structure of the apo-pxr/rxralpha lbd heterotetramer complex |
|
102
|
321
|
4j5wA |
Crystal structure of the apo-pxr/rxralpha lbd heterotetramer complex |
|
2
|
11
|
4jygF |
Crystal structure of rarbeta lbd in complex with agonist bms411 [4-{[(5,5-dimethyl-8-phenyl-5,6-dihydronaphthalen-2-yl)carbonyl]amino}benzoic acid] |
|
25
|
78
|
4i9oA |
Crystal structure of gackix l664c tethered to 1-10 |
|
3
|
10
|
4jyhC |
Crystal structure of rarbeta lbd in complex with selective agonist bms948 [4-{[(8-phenylnaphthalen-2-yl)carbonyl]amino}benzoic acid] |
|
2
|
9
|
4jyiF |
Crystal structure of rarbeta lbd in complex with selective partial agonist bms641 [3-chloro-4-[(e)-2-(5,5-dimethyl-8-phenyl-5,6-dihydronaphthalen-2-yl)ethenyl]benzoic acid] |
|
99
|
318
|
4j5xA |
Crystal structure of the sr12813-bound pxr/rxralpha lbd heterotetramer complex |
|
81
|
259
|
4j5xC |
Crystal structure of the sr12813-bound pxr/rxralpha lbd heterotetramer complex |
|
4
|
16
|
4heeY |
Crystal structure of ppargamma in complex with compound 13 |
|
2
|
10
|
4g20B |
Structural basis for the accommodation of bis- and tris-aromatic derivatives in vitamin d nuclear receptor |
|
2
|
10
|
4g2hB |
Structural basis for the accommodation of bis- and tris-aromatic derivatives in vitamin d nuclear receptor |
|
2
|
11
|
4g1dB |
Structural basis for the accommodation of bis- and tris-aromatic derivatives in vitamin d nuclear receptor |
|
2
|
11
|
4g21B |
Structural basis for the accommodation of bis- and tris-aromatic derivatives in vitamin d nuclear receptor |
|
2
|
10
|
4g1zB |
Structural basis for the accommodation of bis- and tris-aromatic derivatives in vitamin d nuclear receptor |
|
2
|
10
|
4g1yB |
Structural basis for the accommodation of bis- and tris-aromatic derivatives in vitamin d nuclear receptor |
|
1
|
11
|
4fgyB |
Identification of a unique ppar ligand with an unexpected binding mode and antibetic activity |
|
96
|
355
|
3qm0A |
Crystal structure of rtt109-ac-coa complex |
|
3
|
12
|
3qt0C |
Revealing a steroid receptor ligand as a unique ppargamma agonist |
|
113
|
432
|
3q66C |
Structure of the vps75-rtt109 histone chaperone-lysine acetyltransferase complex (full-length proteins in space group p6122) |
|
105
|
404
|
3q33A |
Structure of the rtt109-accoa/vps75 complex and implications for chaperone-mediated histone acetylation |
|
110
|
405
|
3q68C |
Structure of the vps75-rtt109 histone chaperone-lysine acetyltransferase complex (full-length proteins in space group p212121) |
|
82
|
274
|
3qahA |
Crystal structure of apo-form human mof catalytic domain |
|
98
|
404
|
3q35A |
Structure of the rtt109-accoa/vps75 complex and implications for chaperone-mediated histone acetylation |
|
3
|
11
|
3p89B |
Fxr bound to a quinolinecarboxylic acid |
|
2
|
11
|
3p88B |
Fxr bound to isoquinolinecarboxylic acid |
|
38
|
119
|
3p1fA |
Crystal structure of the bromodomain of human crebbp in complex with a hydroquinazolin ligand |
|
2
|
12
|
3okiB |
Crystal structure of human fxr in complex with (2s)-2-[2-(4-chlorophenyl)-1h-benzimidazol-1-yl]-n,2-dicyclohexylethanamide |
|
39
|
114
|
3p1eA |
Crystal structure of the bromodomain of human crebbp in complex with dimethyl sulfoxide (dmso) |
|
40
|
115
|
3p1dA |
Crystal structure of the bromodomain of human crebbp in complex with n-methyl-2-pyrrolidone (nmp) |
|
1
|
10
|
3olsC |
Crystal structure of estrogen receptor beta ligand binding domain |
|
2
|
10
|
3omoC |
Fragment-based design of novel estrogen receptor ligands |
|
3
|
10
|
3okhB |
Crystal structure of human fxr in complex with 2-(4-chlorophenyl)-1-[(1s)-1-cyclohexyl-2-(cyclohexylamino)-2-oxoethyl]-1h-benzimidazole-6-carboxylic acid |
|
1
|
10
|
3ollC |
Crystal structure of phosphorylated estrogen receptor beta ligand binding domain |
|
3
|
12
|
3oofB |
Crystal structure of human fxr in complex with 4-({(2s)-2-[2-(4-chlorophenyl)-5,6-difluoro-1h-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)benzoic acid |
|
3
|
12
|
3omkB |
Crystal structure of human fxr in complex with (2s)-2-[2-(4-chlorophenyl)-5,6-difluoro-1h-benzimidazol-1-yl]-2-cyclohexyl-n-(2-methylphenyl)ethanamide |
